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Rezumat. Scopul studiului a fost determinarea principiilor de implementare a modelelor experimentale: 
screening-ul și optimizarea în elaborarea metodelor de analiză farmaceutică. Cele mai cunoscute mo-
dele de screening sunt: factorial cu două niveluri, factorial fracţionat și Placket-Burman, fiind de obicei 
utilizate pentru a selecta cei mai importanţi factori care afectează răspunsurile și pentru a-i elimina pe 
cei nesemnificativi. Cele mai cunoscute modele de optimizare sunt: factorial cu trei niveluri, compozit 
central și Box-Behnken. Modelele de screening permit modelarea doar de ordinul întâi, în timp ce mo-
delele de optimizare permit o suprafaţă de răspuns de ordinul doi. Modelul ar trebui să fie selectat pe 
baza Analizei varianţei, care compară variabilitatea datorată nivelului factorilor cu variabilitatea dato-
rată erorii reziduale. Astfel, proiectarea experimentului ajută la identificarea modului în care variabilele 
independente afectează caracteristicile de performanţă ale unei metode de analiză.
Cuvinte-cheie: proiectarea experimentelor, analiză farmaceutică, design factorial, variabila dependentă, 
variabilă independentă, analiza varianţei.
Abstract. The objective of the study was determination of principles of implementation of experimen-
tal models: screening and optimization in development of methods of pharmaceutical analysis. The 
most well-known screening designs are: two-level full factorial, fractionate factorial and Placket-Bur-
man, being usually used to select the most important factors that affect the responses and to remove 
the insignificant ones. The most well-known optimization designs are: three-level full factorial, central 
composite and Box-Behnken. The screening designs allow modeling only first order response surface, 
while optimization designs allow a second order response surface. The model should be selected based 
on the application of Analysis of Variance, which compares the variability due to the level of factors with 
the variability due to residual error. Therefore, the design of experiment contributes to identify how the 
independent variables affect the analytical method performance characteristics.
Keywords: design of experiments, pharmaceutical analysis, factorial design, dependent variable, inde-
pendent variable, Analysis of Variance.
INTRODUCTION
The notion of quality by design in pharmaceutical 
analysis has been inserted to ensure the quality of 
medicines. ICH Q8 (R1) guideline defines quality by 
design as’ a systematic approach to development 
that begins with predefined objectives and empha-
sizes product and process understanding and pro-
cess control, based on sound science and quality 
risk management [1, 2]”. Quality by design concepts 
is also defined in ICH Q9 (quality risk management) 
and Q10 (pharmaceutical quality system) [2, 3]. 
In recent years, quality by design is applied more 
often to analytical methods, which contributes to 
development of robust and cost-effective analytical 
methods [2, 4-7]. Therefore, the concepts of analyti-
cal quality by design contribute for understanding 
drug excipient interactions and for the measure of 
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critical quality attributes during experiment, pro-
cess, control and also continuous process verifica-
tion [2, 8-11].
Traditionally, the development and optimizati-
on of analytical methods have been carried out by 
analyzing one factor at time. In addition to deman-
ding a high number of experiments, design of expe-
riments may provide better results with few num-
bers of experiments. Design of experiments is a set 
of statistical tools which include screening designs; 
and optimization designs [2, 12-14].
Design of experiments is the main component of 
analytical quality by design. Thus, the present paper 
provides theoretical considerations for implementa-
tion of design of experiments in analytical quality by 
design.
MATERIALS AND METHODS
To identify relevant studies, it was used the 
following academic search engines: Medline, Pub-
Med, the Cochrane Methodology Register, Scopus, 
IET Digital Library (search by titles and abstracts), 
Google Scholar and Science Direct (full-text search). 
The last search was march 2021. It was also used 
supplementary search techniques and sources (`si-
milar articles” function in PubMed, conference abs-
tracts and reference lists).
The general search pattern was as follows: „qua-
lity by design”, „pharmaceutical analysis”, „factorial 
design”, „dependent variable”, „independent varia-
ble”, „Analysis of Variance”.
The search yielded 112 articles, which were further 
filtered manually. All selecting bibliographic sources 
were summarized in a structured, narrative way.
RESULTS AND DISCUSSIONS
Design of experiments is a structured and orga-
nized method for determining the relationships be-
tween input factors affecting one or more output 
responses. Experimental designs may be divided 
into two types: screening designs and optimization 
designs [2, 7].
Screening designs are often used in the first step 
of design of experiments in order to select the most 
important input factors and discard the insignifcant 
ones. Two-level full factorial designs, fractionate 
factorial designs and Placket-Burman designs allow 
one to study a wide number of input factors with 
reduced numbers of experiments, however, they 
also have some limitations. The main limitations of 
two-level full factorial designs rely on the large nu-
mber of experiments required, when compared to 
fractionate factorial designs and Plackett-Burman 
designs. The number of experiments required for 
two-level full factorial designs may be calculated as 
2k, where k is the number of input factors to be stu-
died [2, 4-7]. 
Fractionate factorial designs can be determin-
ed by using a 2k–p design, where p is the number of 
generators chosen to fractionate the design. Thus, 
fractionate factorial designs may not be suitable 
for assessing the interactions among factors. Plac-
kett-Burman designs are special types of two-level 
fractionate factorial designs (resolution III), which 
allow one to study up to N-1 input factors with N ex-
periments, which should be multiple of 4 [2, 4-11].
Three-level full factorial designs, central compo-
site designs, and Box-Behnken designs are the most 
used optimization designs because they allow mo-
deling complex response surface. One of the most 
important limitations of screening designs rely on 
the fact that they only allow modeling 1st order (li-
near) response surface, because they have only two 
level for each input factor. Optimization designs 
uses 3 to 5 levels of each input factors, which allow 
modeling 2nd order (quadratic) response surface [2, 
12-14]. 
Three-level full factorial design are often used 
only when two or three input factors need to be stu-
dy, because an increased number of experiments is 
required. The number of experiments required may 
be calculated as 3k, where k is the number of input 
factors to be studied [2, 12-14]. 
Central composite designs are one of the most 
used optimization designs because they use 5 level 
of each input factor with a reduced number of expe-
riments required, when compared to three-level full 
factorial design [2, 12-14]. 
Box-Behnken design are special types of 
three-level fractionate factorial designs, which 
allows modeling 1st and 2nd order response surfa-
ces. These designs are more cost-effective than 
three-level full factorial designs, particularly for lar-
ge number of input factors [2, 12-14].
Mathematical model should be selected based on 
the application of Analysis of Variance (ANOVA). The 
main idea of ANOVA is to compare the variability due 
to treatment (varying the level of input factors) with 
the variability due to residual error. Based on ANOVA, 
we can decide to include or to exclude the coeffici-
ents of linear terms, interaction terms and quadratic 
terms. This decision is based on p-values for each 
coefficient regression term. When the regression 
coefficient term is not different from 0 (p-value > 
0.05), it indicates that the output response is not 
affect by varying the input factor levels. Thus, this 
coefficient regression term may be excluded from 
the regression model [2, 12-14].
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Recently, design of experiment has been used 
in the rational development and optimization of 
analytical methods. Culture media composition, 
mobile phase composition, flow rate, time of incuba-
tion are examples of input factors (independent va-
riables) that may the screened and optimized using 
design of experiment. Several output responses (de-
pendent variables), such as retention time, resoluti-
on between peaks, microbial growth, among other 
responses were found in literature [2, 12-14] (table 1).
Table 1. Some applications of design of experiments in pharmaceutical analysis
Object of study Type of design Application of design Reference
Central composite design Oral Drug Delivery
To identify critical factors, their  
interactions and ideal process  






Optimization of instrumental  
parameters for spray drying  
of riseridone nanosuspension
[16]
Factorial design Oral Drug Delivery
Implementation of quality by design 





Optimization of micro-emulsion  
formulation
[18]




Optimization, sensitivity analysis  
and robustness study of analytical 
method
[19]
Factorial factorial design 
and Box-Behnken design
Analytical study Screening and optimization of factors [20]
Journal of Pharmaceutical Science Invention. 
2015, 4(1), p. 29-41.
5. Chowdary K. P., Shankar K. R., Kumar P. S. Re-
cent research on QbD approach in formulation 
development: A review. International Journal of 
Chemical Science and Technology. 2014, 4(1), p. 
282-292.
6. Trivedi B. Quality by desing (QbD) in pharmace-
uticals. Int J Pharm Pharm Sci. 2012, 4, p. 17-29. 
7. Jain S. Quality by design (QBD): a comprehen-
sive understanding of implementation and 
challenges in pharmaceuticals development. 
Int. J. Pharm. Pharm. Sci. 2014, 6, p. 29-35.
8. Kumar P. M., Ghosh A. Development and evalu-
ation of silver sulfadiazine loaded microsponge 
based gel for partial thickness (second degree) 
burn wounds. European Journal of Pharmace-
utical Sciences. 2017, 96(1), p. 243-254. https://
doi.org/10.1016/j.ejps.2016.09.038
9. Badawi M. A., El-Khordagui L. K. A quality by de-
sign approach to optimization of emulsions for 
electrospinning using factorial and D-optimal 
designs. European Journal of Pharmaceutical 
Sciences. 2014, 58, p. 44-54. https://doi.or-
g/10.1016/j.ejps.2014.03.004
10. Charoo N. A., Shamsher A. A., Zidan A. S. et al. 
CONCLUSIONS
Design of experiment’s tools help to identify and 
explain how critical analytical parameters (indepen-
dent variables) affects the analytical method per-
formance characteristics (dependent variables) and 
therefore, the analytical target profle. Implementa-
tion of design of experiment’s tools provides robust 
analytical methods, which plays significant role in 
drug product development.
REFERENCES
1. ICH. (2007). Draft consensus guideline: phar-
maceutical development annex to Q8. Available 
at:, MEDIA4349.pdf (accessed 11/08/2021).
2. Mohurle S. M., Asnani A., Chaple D. R. et al. Quality 
by Design (QbD): An Emerging Trend in Impro-
ving Quality and Development of Pharmaceuti-






4. Bhattacharya J. Quality Risk Management–Un-
derstanding and control the risk in pharmace-
utical manufacturing industry. International 




Quality by design approach for formulation de-
velopment: A case study of dispersible tablets. 
International Journal of Pharmaceutics. 2012, 
423(2), p. 167-178. https://doi.org/10.1016/j.
ijpharm.2011.12.024
11. Fontdecaba S., Grima P., Martorell X. T. Analy-
zing DOE With Statistical Software Packa-
ges: Controversies and Proposals. The Ameri-
can Statistician. 2014, 68(3), p. 205-211. DOI: 
10.1080/00031305.2014.923784
12. Zhang L., Mao S. Application of quality by design 
in the current drug development. Asian Journal 
of Pharmaceutical Sciences. 2017, 12(1), p. 1-8. 
https://doi.org/10.1016/j.ajps.2016.07.006
13. Shah B., Khunt D., Bhatt H. et al., Application of 
quality by design approach for intranasal de-
livery of rivastigmine loaded solid lipid nano-
particles: Effect on formulation and charac-
terization parameters. Eur. J. Pharm. Sci. 
2015, 78, p. 54–66. https://doi.org/10.1016/j.
ejps.2015.07.002
14. Politis S. N., Colombo P., Coxlombo G., et al. De-
sign of experiments (DoE) in pharmaceutical 
development. Drug Develop. Ind. Pharm. 2017, 
43, p. 889–901. https://doi.org/10.1080/03639
045.2017.1291672
15. Jivani R. R., Patel C. N., Jivani N. P. Statistical 
design of experiments on fabrication of bilayer 
tablet of narrow absorption window drug: De-
velopment and In vitro characterization. Indian 
J. Pharm. Sci.2012, 74, p. 302–311.
16. Nair A., Khunt D., Misra M. Application of quality 
by design for optimization of spray drying pro-
cess used in drying of Risperidone nanosus-
pension. Powder Technol. 2019, 342, p. 156–65. 
https://doi.org/10.1016/j.powtec.2018.09.096
17. Patel N., Jain S., Madan P. et al. Applicati-
on of design of experiments for formulati-
on development and mechanistic evalua-
tion of iontophoretic tacrine hydrochloride 
delivery. Drug Development and Industrial 
Pharmacy. 2016, 42(11), p. 1894-1902, DOI: 
10.1080/03639045.2016.1181646
18. Malladi M., Jukanti R. Formulation development 
and evaluation of a novel bi-dependent cla-
rithromycin gastroretentive drug delivery sys-
tem using Box-Behnken design. J. Drug Deliver. 
Sci. Technol., 2016, 35, p. 134–145. https://doi.
org/10.1016/j.jddst.2016.06.003
19. Tol T., Kadam N., Raotole N. et al. A simultaneous 
determination of related substances by high 
performance liquid chromatography in a drug 
product using quality by design approach. J. 
Chromatogr., 2016, 1432, p. 26–38. https://doi.
org/10.1016/j.chroma.2015.12.080 
20. Sakr M., Hanafi R., Fouad M. et al.  Design and 
optimization of a luminescent Samarium com-
plex of isoprenaline: A chemometric approach 
based on Factorial design and Box-Behnken 
response surface methodology. Spectrochim. 
Acta Mol. Biomol. Spectrosc. 2019, 208, p. 114–
123. https://doi.org/10.1016/j.saa.2018.09.061 
ID-UL ORCID AL AUTORILOR
Elena Donici  
https://orcid.org/0000-0001-6862-7449 
Vladimir Valica 
https://orcid.org/0000-0002-1068-5504 
Ecaterina Mazur 
https://orcid.org/0000-0003-0725-8410 
Livia Uncu 
https://orcid.org/0000-0003-3453-2243 
